News

Overlooked for Decades: P3 Peptide May Be a Hidden Culprit in Alzheimer’s Disease

Alzheimer’s research has focused on amyloid beta for decades, but a biochemist at the University of California, Santa Cruz now argues that a smaller, long-dismissed peptide called P3 may also drive the disease, forming harmful protein clumps even faster than amyloid beta. The case is laid out in a commentary by professor Jevgenij Raskatov published in ChemBioChem.

Key Points

  • P3 was long assumed to be harmless, water-soluble and incapable of forming amyloid deposits, assumptions that were never adequately verified
  • Evidence suggests P3 aggregates even faster than amyloid beta and is potentially neurotoxic
  • P3 may interact with amyloid beta, influencing how it accumulates in the brain and how toxic it becomes
  • Raskatov proposes renaming P3 “Amyloid alpha” (Aα)
  • Alzheimer’s affects about 35 million people worldwide, costs exceed $800 billion a year, and cases are expected to double by 2050
  • More than 400 clinical trials have mostly targeted amyloid beta, with limited success

Dismissed as Harmless, on Assumptions Never Verified

Amyloid beta originates from the amyloid precursor protein (APP), cut by beta-secretase and then gamma-secretase; the Aβ42 variant, most prone to aggregation, has been the central target of drug development for decades. P3 takes a different route: alpha-secretase cuts first, followed by gamma-secretase. According to Raskatov, scientists long assumed P3 could not form amyloid deposits, was not toxic to cells and would simply dissolve, yet those assumptions were never adequately tested.

Recent evidence shows P3 forms microscopic clumps and fibrils, potentially aggregating faster than amyloid beta, and may interact with it, influencing accumulation and toxicity. “The P3 peptide is, most likely, not the innocent bystander it was commonly thought to be. There’s still more research to be done. But this could turn Alzheimer’s research on its head,” Raskatov said, adding that “P3 is a distinct aggregating peptide that is itself potentially neurotoxic and may be contributing to Alzheimer’s disease.”

Limited Success So Far, and a Call for New Directions

Alzheimer’s is the most widespread neurodegenerative disease, affecting approximately 35 million people and generating annual costs exceeding $800 billion, with cases expected to double by 2050. More than 400 clinical trials have investigated potential drugs, most targeting amyloid beta; many failed or delivered only modest benefits, and some treatments have been associated with brain hemorrhages and strokes. Recently approved antibody treatments such as Lecanemab and Donanemab have shown limited benefit.

“Progress has been extremely slow, and the current state of the art in Alzheimer’s therapy leaves much to be desired,” Raskatov said. “We need fundamentally new approaches to the problem,” including, his commentary argues, serious study of P3’s role in the disease.

Source: ScienceDaily / UC Santa Cruz

(Featured image is AI-generated for illustration purposes.)